Global Core Electronic Medicinal Product Information (ePI)
1.1.0 - trial-use International flag

Global Core Electronic Medicinal Product Information (ePI), published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/emedicinal-product-info/ and changes regularly. See the Directory of published versions

: RegulatedAuthorization - WonderDrug 500 mg

Page standards status: Informative

Raw json | Download

{
  "resourceType" : "RegulatedAuthorization",
  "id" : "ra-epi-type2-example-paracetamol",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: RegulatedAuthorization ra-epi-type2-example-paracetamol</b></p><a name=\"ra-epi-type2-example-paracetamol\"> </a><a name=\"hcra-epi-type2-example-paracetamol\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-RegulatedAuthorization-uv-epi.html\">RegulatedAuthorization (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/MA-123456789</p><p><b>subject</b>: <a href=\"Bundle-bundle-epi-type2-example-paracetamol.html#http-//hl7.org/fhir/uv/emedicinal-product-info/MedicinalProductDefinition/mpd-epi-type2-example-paracetamol\">MedicinalProductDefinition: identifier = http://ema.europa.eu/identifier#WONDERDRUG-500MG; domain = Human use; status = Active; legalStatusOfSupply = Medicinal product subject to medical prescription</a></p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 220000000061}\">Marketing Authorisation</span></p><p><b>region</b>: <span title=\"Codes:{urn:iso:std:iso:3166 EE}\">Estonia</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">Active</span></p><p><b>holder</b>: <a href=\"Organization-org-epi-type2-example-acme.html\">Organization Acme Pharma Inc.</a></p></div>"
  },
  "identifier" : [
    {
      "system" : "http://ema.europa.eu/identifier",
      "value" : "MA-123456789"
    }
  ],
  "subject" : [
    {
      🔗 "reference" : "http://hl7.org/fhir/uv/emedicinal-product-info/MedicinalProductDefinition/mpd-epi-type2-example-paracetamol"
    }
  ],
  "type" : {
    "coding" : [
      {
        "system" : "https://spor.ema.europa.eu/rmswi",
        "code" : "220000000061",
        "display" : "Marketing Authorisation"
      }
    ]
  },
  "region" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "EE",
          "display" : "Estonia"
        }
      ]
    }
  ],
  "status" : {
    "coding" : [
      {
        "system" : "http://hl7.org/fhir/publication-status",
        "code" : "active",
        "display" : "Active"
      }
    ]
  },
  "holder" : {
    🔗 "reference" : "Organization/org-epi-type2-example-acme"
  }
}